Compare SRRK & TEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | TEX |
|---|---|---|
| Founded | 2012 | 1933 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.7B |
| IPO Year | 2018 | 1994 |
| Metric | SRRK | TEX |
|---|---|---|
| Price | $41.57 | $52.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 14 |
| Target Price | $70.44 | ★ $76.09 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 11-13-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 1.34% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $5,421,000,000.00 |
| Revenue This Year | N/A | $50.31 |
| Revenue Next Year | $2,404.46 | $7.48 |
| P/E Ratio | ★ N/A | $253.50 |
| Revenue Growth | N/A | ★ 5.73 |
| 52 Week Low | $27.07 | $41.70 |
| 52 Week High | $61.76 | $74.69 |
| Indicator | SRRK | TEX |
|---|---|---|
| Relative Strength Index (RSI) | 30.05 | 34.89 |
| Support Level | $39.69 | $50.64 |
| Resistance Level | $48.59 | $62.24 |
| Average True Range (ATR) | 1.89 | 2.07 |
| MACD | -0.23 | -0.07 |
| Stochastic Oscillator | 14.72 | 7.66 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).